In8Bio (INAB) Other Working Capital Changes (2020 - 2026)

In8Bio's (INAB) quarterly Other Working Capital Changes came in at -$15000.0 in Q3 2022, down 128.85% quarter-over-quarter from $52000.0 in Q1 2021.

Analysis

In8Bio (INAB) Other Working Capital Changes (2020 - 2026) Analysis & Trends

In8Bio has disclosed Other Working Capital Changes across 2 years of filings, most recently posting -$15000.0 for Q3 2022.

In Q2 2026, Other Working Capital Changes rose 43.79% year-over-year to -$181000.0; the TTM figure through Jun 2026 stood at $25000.0 (up 101.28% YoY), while the FY2025 annual figure was -$670000.0, up 64.53% from the prior year.
Other Working Capital Changes came in at -$181000.0 for Q2 2026 at In8Bio, down from -$67000.0 in the prior quarter.
In the past five years, Other Working Capital Changes ranged from a high of $52000.0 in Q1 2021 to a low of -$15000.0 in Q3 2022.
Average Other Working Capital Changes over 5 years is -$77944.4, with a median of -$283000.0 recorded in 2024.
Year-over-year, Other Working Capital Changes soared 264.79% in 2022 and plunged 1288.89% in 2023.
Over 2 years, Other Working Capital Changes stood at $52000.0 in 2021, then plunged by 128.85% to -$15000.0 in 2022.
Per Business Quant data, the three most recent Other Working Capital Changes figures were -$181000.0 in Q2 2026, -$67000.0 in Q1 2026, and -$291000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Krystal Biotech	10.21 Bn	9.37 Bn	112.79 Mn
2	CRISPR Therapeutics AG	5.04 Bn	5.04 Bn	-
3	Iovance Biotherapeutics	3.65 Bn	3.36 Bn	55.72 Mn
4	Legend Biotech	3.54 Bn	2.57 Bn	251.50 Mn
5	uniQure	2.95 Bn	2.95 Bn	5.49 Mn
6	Beam Therapeutics	2.55 Bn	2.55 Bn	-
7	Precigen	2.39 Bn	2.39 Bn	52.17 Mn
8	Sarepta Therapeutics	2.16 Bn	1.37 Bn	251.87 Mn
9	Vericel	1.93 Bn	1.77 Bn	56.40 Mn
10	In8Bio	21.41 Mn	21.41 Mn	-

Historic Data

Download Data